One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Acute Lymphoblastic Leukemia Therapeutics Market

[ 英語タイトル ] Acute Lymphoblastic Leukemia Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

Product Code : MDHC0088638
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 115
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Bristol Myer Squibb Company
- Celegene Corporation
- Eisai Co Ltd
- Erytech Pharma
- F. Hoffmann-La Roche Ltd
- Genmab A/S
- GlaxoSmithKline PLC
- Novartis AG
- Pfizer Inc.
- Sanofi SA

[Report Description]

One of the major factors responsible for the growth of this market includes the rising occurrence of acute lymphoblastic leukemia (ALL) globally. The number of new cases being recorded each year is around 1.7 per 100,000 men and women per year. It has been estimated by the American Cancer Institute that in 2019, there will be around 5,930 new cases of ALL i.e. 3,280 in males and 2,650 in females. In addition, by 2020, it has been estimated that the number of cases of ALL may range around 0.4 to 2 per 100,000 population in the Asia-Pacific and South American countries.

There is a rise in the number of cases primarily due to the adoption of western lifestyles, including dietary changes and sedentary lifestyles. Moreover, globally, the prevalence is expected to increase during the forecast period, which shall be the major factor for the growth of this market.

Key Market Trends

Chemotherapy is Expected to Dominate the Type of Therapy Segment

The American Cancer Association stated that chemotherapy is the main treatment for the people suffering from acute lymphoblastic leukemia (ALL), and it has three phases, such as remission, consolidation, and maintenance. Chemotherapy uses cytotoxic drugs for the destruction of cancer cells.

Amsacrine (NordMedica), cyclophosphamide (Baxter), and cytarabine (Pfizer) are some of the drugs that are used for chemotherapy in ALL. Global pharmaceutical players, such as Baxter International, and Pfizer, are providing these drugs. ALL is the most common cancer in children, adolescents, and young adults younger than 20 years, accounting for 19.8% of all cancer cases in this age group, as per a 2019 report by the Leukemia & Lymphoma Society. Hence, the market for chemotherapy is also expected to boost due to high prevalence of ALL, especially among children.

North America to Dominate the Market Over the Forecast Period

North America is expected to dominate this market, due to the rising number of cases of this disease in the region, owing to genetic factors, environmental factors, and radiation. Moreover, favorable government policies, well-established healthcare infrastructure, and the presence of multinational companies make this region dominant in this market.

Asia-Pacific is also expected to register a high CAGR during the forecast period, owing to several factors, such as high unmet clinical needs, huge patient pool, and the rising awareness about early diagnosis in emerging countries.

Competitive Landscape

The market for acute lymphoblastic leukemia is moderately competitive and consists of the big players as well as the mid-sized companies. Owing to the rising focus of most of the pharmaceutical companies on oncology, it is expected that few new small-sized companies will also penetrate the market in the near future.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in the Incidences of Acute Lymphoblastic Leukemia
4.2.2 Increasing Initiatives Taken by the Government and Private Organizations
4.3 Market Restraints
4.3.1 Stringent Regulatory Pathways
4.3.2 High Cost Asscoiated with the Treatment
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type of Cell
5.1.1 B-cell ALL
5.1.2 T-cell ALL
5.1.3 Philadelphia Chromosome: Positive (Ph+) and Negative (Ph-) ALL
5.2 By Type of Therapy
5.2.1 Chemotherapy Hyper - CVAD Regimen CALGB 8811 Regimen Linker Regimen Nucleoside Inhibitors Other Types of Therapies
5.2.2 Targeted Therapy
5.2.3 Radiation Therapy
5.2.4 Stem Cell Transplantation
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Bristol Myer Squibb Company
6.1.2 Celegene Corporation
6.1.3 Eisai Co Ltd
6.1.4 Erytech Pharma
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 Genmab A/S
6.1.7 GlaxoSmithKline PLC
6.1.8 Novartis AG
6.1.9 Pfizer Inc.
6.1.10 Sanofi SA




Recommended reports